Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Ground

Published November 13, 2026 · Updated November 14, 2026

Trump Administration Will Fund New Research on Controversial Psychedelic Drug Ibogaine

Read the full story at Ground

On Thursday, Health Secretary Robert F. Kennedy Jr. announced the government is awarding up to $4.9 million for the first U.S. studies of ibogaine to.

Surfaced by 5 Google Alerts

  • Ibogaine
  • Psychedelic crime
  • Psychedelics south america
  • Psychedelic press release
  • LSD